99mTc-CNDG Injection in the Diagnosis of Malignant Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-11

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, 18F-fluorodeoxyglucose (18F-FDG) is the most widely used tumor imaging agent in clinical practice. However, the production of 18F requires accelerators and is associated with relatively high diagnostic costs, which to some extent limits its widespread clinical application. In comparison to Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) devices are more abundant and offer lower diagnostic expenses. With the utilization of Cadmium Zinc Telluride (CZT) crystals in SPECT and advancements in image reconstruction techniques, the resolution and sensitivity of SPECT is continually improving. Therefore, the development of a simplified and cost-effective novel SPECT tumor imaging agent holds significant practical significance. This study involved the design and synthesis of a glucose-derived ligand with a linker containing seven methylene units and an isonitrile group (CN7DG). The CN7DG ligand was labeled with 99mTc to prepare a more lipophilic 99mTc-CN7DG complex, aiming to investigate a novel SPECT imaging agent for tumor imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

99mTc-CNDG SPECT/CT in Brain Tumors

NCT06362304

Intracranial Tumor

RECRUITING NA

Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection

NCT06206642

Malignant Neoplasm

COMPLETED NA

Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study

NCT06753513

Malignant Tumors Solid Tumor Malignancy

NOT_YET_RECRUITING

99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients

NCT01737112

Lung Cancer

UNKNOWN EARLY_PHASE1

BBPA PET/CT in Patients With Malignant Tumors

NCT05987098

Malignant Tumors

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

99mTc-CNDG SPECT/CT

Inject 99mTc-CNDG and then perform SPECT/CT scan.

Group Type EXPERIMENTAL

99mTc-CNDG SPECT/CT

Intervention Type DIAGNOSTIC_TEST

Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

99mTc-CNDG SPECT/CT

Explore the imaging characteristics of 99mTc-CNDG and its diagnostic efficacy in tumor patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-70 years old
* Patients diagnosed with malignant glioma, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, or other malignant tumors through imaging techniques such as MRI, CT, and ultrasound, and who are scheduled for surgical resection or biopsy
* Solid tumor sizes greater than 2cm
* Voluntarily agree to participate and sign an informed consent form
* Can provide complete surgical records, pathological results, control data, and clinical follow-up results

Exclusion Criteria

* Pre-treatment such as chemotherapy and targeted therapy has been administered
* Pregnancy and breastfeeding
* Claustrophobia
* The condition is severe and difficult to cooperate with
* Unable to obtain relevant control imaging data and clinical information

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No